BS_X23724NJ
high-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- high-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- high-grade glioma
- age_years
- 8.808
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HYPOXIA+0.513
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.499
- TNFA_SIGNALING_VIA_NFKB+0.498
- MYC_TARGETS_V2+0.474
- IL6_JAK_STAT3_SIGNALING+0.455
- INFLAMMATORY_RESPONSE+0.455
- INTERFERON_ALPHA_RESPONSE+0.451
- COAGULATION+0.445
- ANGIOGENESIS+0.422
- GLYCOLYSIS+0.410
Top 10 suppressed
- PROTEIN_SECRETION-0.166
- MITOTIC_SPINDLE-0.153
- WNT_BETA_CATENIN_SIGNALING-0.133
- FATTY_ACID_METABOLISM-0.131
- BILE_ACID_METABOLISM-0.124
- UV_RESPONSE_DN-0.113
- OXIDATIVE_PHOSPHORYLATION-0.083
- SPERMATOGENESIS-0.081
- HEME_METABOLISM-0.079
- ANDROGEN_RESPONSE-0.012
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_QWTE1CWR | high-grade glioma | — | 0.909 |
| 2 | BS_31TF0P1N | ATRT | — | 0.905 |
| 3 | BS_P0QF87WC | high-grade glioma | — | 0.898 |
| 4 | BS_4T0HPZDC | Posterior Fossa Ependymoma | — | 0.890 |
| 5 | TCGA-FD-A5C1-01A-11R-A28M-07 | — | — | 0.886 |
| 6 | TCGA-FD-A6TD-01A-51R-A33J-07 | — | — | 0.886 |
| 7 | BS_M85CXHDV | high-grade glioma | — | 0.884 |
| 8 | MDT-AP-1245 | Med | Medulloblastoma | 0.879 |
| 9 | BS_4T0HPZDC | EPN | Posterior Fossa EPN | 0.872 |
| 10 | BS_KXMYBQ6N | EPN | EPN Tumor | 0.871 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HYPOXIA | 0.513 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.499 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.498 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.474 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.455 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.455 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.451 | Inavolisib | — uncovered |
| COAGULATION | 0.445 | Binimetinib | — uncovered |
| ANGIOGENESIS | 0.422 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.410 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.396 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.339 | Inavolisib | — uncovered |
| COMPLEMENT | 0.320 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.318 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.305 | Inavolisib | — uncovered |
| APOPTOSIS | 0.300 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.293 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.293 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.266 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.250 | Idelalisib | — uncovered |